Skip To Main Content

CD25 MAb

(RG6292) 

Solid Tumor

Phase I

A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors

NCT04642365